

## Special Issue

# Regulation of Bone Homeostasis: Crosstalk Between Osteoblasts and Osteoclasts

### Message from the Guest Editor

Understanding the molecular and cellular mechanisms that regulate osteoblast–osteoclast interactions is crucial for developing novel therapeutic strategies to treat bone-related diseases. This Special Issue aims to explore the latest advances in bone biology, focusing on signaling pathways, cellular communication, extracellular vesicles, and regulatory mechanisms that maintain bone homeostasis. We welcome original research and review articles on topics, including but not limited to the following research areas: osteoblast–osteoclast crosstalk, the impact of inflammatory and metabolic factors on bone remodeling, and emerging therapeutic targets for bone disorders. Studies investigating the intersection between vascular and skeletal systems are also encouraged. By gathering insights from multidisciplinary approaches—including molecular biology, bioinformatics, genetics, and translational medicine—this Special Issue seeks to provide a comprehensive understanding of the regulatory networks controlling bone metabolism.

### Guest Editor

Dr. Xiangguo Che

Korea Mouse Phenotyping Center (KMPC), Department of Biochemistry and Cell Biology, Cell and Matrix Research Institute, School of Medicine, Kyungpook National University, Daegu 41944, Republic of Korea

### Deadline for manuscript submissions

31 October 2025



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/235403](https://mdpi.com/si/235403)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPUS / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).